Mesoblast is a clinical-stage biotechnology company that develops allogeneic cellular medicines derived from mesenchymal precursor cells and mesenchymal stromal cells sourced from bone marrow, which modulate the immune system to treat severe inflammatory and cardiovascular conditions without requiring donor-recipient matching or immune suppression. The company generates revenue through product sales of its FDA-approved therapy for steroid-refractory acute graft versus host disease in pediatric patients, as well as milestone payments and royalties from partnerships with global pharmaceutical companies that commercialize Mesoblast's therapies in Japan, Europe, Latin America, and China. Mesoblast's competitive advantages include orphan drug and biologic exclusivity, a robust patent portfolio extending protection beyond the current decade, and a pipeline of late-stage candidates in chronic heart failure and degenerative disc disease supported by strategic manufacturing partnerships and a direct sales force targeting transplant centers and specialty markets.